abstract |
This technology aims to provide novel drugs. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs) characterized in that at least one ISVD binds TNFα and at least two ISVDs bind IL-23. The present technology also provides nucleic acids, vectors and compositions. |